• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Zai Lab Limited

    6/18/24 4:19:43 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZLAB alert in real time by email
    S-8 1 zailab-formsx8june182024.htm S-8 Document

    As filed with the Securities and Exchange Commission on June 18, 2024
    Registration No. 333-            
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     
     
    Zai Lab Limited
    (Exact name of registrant as specified in its charter)
     
     
     
    Cayman Islands 98-1144595
    (State or other jurisdiction of
    incorporation or organization)
     
    (I.R.S Employer
    Identification No.)
    4560 Jinke Road
    Bldg. 1, Fourth Floor, Pudong,
    Shanghai, China
     201210
    314 Main Street
    4th Floor, Suite 100
    Cambridge, MA, USA
     02142
    (Address of Principal Executive Offices) (Zip Code)
    Zai Lab Limited 2024 Equity Incentive Plan
    (Full title of the plan)
    F. Ty Edmondson
    314 Main Street
    4th Floor, Suite 100
    Cambridge, MA 02142
    Telephone: +1 (857) 706-2604
    (Name, address, and telephone number, including area code, of agent for service)
     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
     
    Large Accelerated filer ☒  Accelerated filer ☐
    Non-accelerated filer ☐  Smaller reporting company ☐
       Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐



    EXPLANATORY NOTE
    This Registration Statement on Form S-8 is being filed to register 99,208,743 ordinary shares, par value $0.000006 per share, of Zai Lab Limited (the “Registrant”) that may be issued pursuant to the Zai Lab Limited 2024 Equity Incentive Plan (the “Plan”).
    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
    Information required by Part I to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the Note to Part I of Form S-8. The documents containing the information specified in Part I will be delivered to participants covered by the Plan, as specified by Rule 428(b)(1) under the Securities Act.
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3. Incorporation of Documents by Reference
    The following documents previously filed with the Securities and Exchange Commission (the “Commission”) by the Registrant are incorporated herein by reference:
    (a)The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on February 27, 2024 (the “2024 Form 10-K”);
    (b)The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the Commission on May 8, 2024;
    (c)The Registrant’s Current Reports on Form 8-K, filed with the Commission on February 8, 2024, June 11, 2024, and June 18, 2024; and
    (d)The description of the Registrant’s ordinary shares incorporated by reference in the Registrant’s Registration Statement on Form 8-A (File No. 001-38205), filed with the Commission on September 14, 2017, including any amendment and report subsequently filed for purpose of updating that description, including the Description of Securities Registered contained in Exhibit 4.5 to the 2024 Form 10-K.
    To the extent that any information contained in any Current Report on Form 8-K, or any exhibit thereto, was furnished to, rather than filed with, the Commission, including any information furnished pursuant to Item 2.02 or Item 7.01 of the Registrant’s Current Reports on Form 8-K, such information or exhibit is specifically not incorporated by reference into this Registration Statement.
    In addition, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement, which indicates that all securities offered hereunder have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.
    Any document or any statement contained in a document incorporated or deemed to be incorporated by reference in this Registration Statement will be deemed to be modified or superseded to the extent that a subsequently filed document or a statement contained in this Registration Statement or in any other later filed document which also is or is deemed to be incorporated by reference in this Registration Statement modifies or



    supersedes such document or such statement in such document. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to be a part of this Registration Statement.
    Item 4. Description of Securities
    Not applicable.
    Item 5. Interests of Named Experts and Counsel
    Not applicable.
    Item 6. Indemnification of Directors and Officers
    The Companies Act (Revised) of the Cayman Islands does not limit the extent to which a company’s articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime.
    The Registrant’s Sixth Amended and Restated Articles of Association provides that the Registrant shall indemnify its directors and officers (each an indemnified person) against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such indemnified person, other than by reason of such person’s own willful neglect or default, in or about the conduct of the Registrant’s business or affairs or in the execution or discharge of his or her duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such indemnified person in defending (whether successfully or otherwise) any civil proceedings concerning the Registrant or its affairs in any court whether in the Cayman Islands or elsewhere.
    Pursuant to the indemnification agreements the Registrant entered into with each of its directors and executive officers, the Registrant agreed to indemnify its directors and executive officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being such a director or officer.
    Item 7. Exemption from Registration Claimed
    Not applicable.




    Item 8. Exhibits
    The Exhibits listed on the accompanying Exhibit Index are filed as a part of, or incorporated by reference into, this Registration Statement.
    EXHIBIT INDEX
     
    Exhibit  Description
    4.1
    Sixth Amended and Restated Memorandum and Articles of Association of Zai Lab Limited (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38205) filed on June 22, 2022)
    4.2  
    Registrant’s Specimen Certificate for Ordinary Shares (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-8 (File No. 333-264800) filed on May 9, 2022)
    4.3  
    Form of American Depositary Receipt (incorporated by reference to Form 424B3 (File No. 333-220256), filed on March 30, 2022)
    4.4  
    Form of Deposit Agreement (incorporated by reference to Exhibit 4.1 to Amendment No. 2 to the Registrant’s Registration Statement on Form F-1 (File No. 333-219980) filed on September 1, 2017)
    4.5#
    Zai Lab Limited 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K (File No. 001-38205) filed on June 18, 2024)
    5.1
    Opinion of Travers Thorp Alberga regarding the validity of the ordinary shares being registered
    23.1
    Consent of KPMG LLP, an independent registered accounting firm, regarding the consolidated financial statements of Zai Lab Limited
    23.2
    Consent of Deloitte Touche Tohmatsu Certified Public Accountants LLP, an independent registered accounting firm, regarding the consolidated financial statements of Zai Lab Limited
    23.3
    Consent of Travers Thorp Alberga (included in Exhibit 5.1)
    24.1
    Power of Attorney (included on the signature page of this Registration Statement under the caption “Power of Attorney”)
    107
    Filing Fee Table
    # Management contract or compensatory plan, contract, or arrangement

    Item 9. Undertakings
    (a)The undersigned Registrant hereby undertakes:
    (1)To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
    (i)To include any prospectus required by Section 10(a)(3) of the Securities Act;
    (ii)To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of a prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum



    aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and
    (iii)To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;
    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above shall not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
    (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and
    (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (b)The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (c)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.



    SIGNATURES
    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, State of Massachusetts, on June 18, 2024.
     

    ZAI LAB LIMITED
    By:
     /s/ F. Ty Edmondson
    Name: F. Ty Edmondson
    Title: Chief Legal Officer




    POWER OF ATTORNEY
    Each person whose signature appears below hereby constitutes and appoints Samantha (Ying) Du, Yajing Chen, and F. Ty Edmondson, and each of them singly, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution and re-substitution, for and in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them singly, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or either of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
    SignatureTitleDate
    /s/ Samantha (Ying) DuChief Executive Officer and Chairperson of the Board of DirectorsJune 18, 2024
    Samantha (Ying) Du(Principal Executive Officer)
    /s/ Yajing ChenChief Financial OfficerJune 18, 2024
    Yajing Chen(Principal Financial and Accounting Officer)
    /s/ Kai-Xian ChenDirectorJune 18, 2024
    Kai-Xian Chen
    /s/ John DiekmanDirectorJune 18, 2024
    John Diekman
    /s/ Richard GaynorDirectorJune 18, 2024
    Richard Gaynor
    /s/ Nisa LeungDirectorJune 18, 2024
    Nisa Leung
    /s/ William LisDirectorJune 18, 2024
    William Lis
    /s/ Scott MorrisonDirectorJune 18, 2024
    Scott Morrison
    /s/ Leon O. Moulder, Jr.DirectorJune 18, 2024
    Leon O. Moulder, Jr.
    /s/ Michel VounatsosDirectorJune 18, 2024
    Michel Vounatsos
    /s/ Peter WirthDirectorJune 18, 2024
    Peter Wirth

    Get the next $ZLAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZLAB

    DatePrice TargetRatingAnalyst
    8/25/2025$52.00Buy
    Jefferies
    3/7/2025$55.00Sector Outperform
    Scotiabank
    3/3/2025$29.00 → $36.10Buy → Neutral
    BofA Securities
    12/14/2023$47.50Overweight
    Morgan Stanley
    8/10/2023$70.00Overweight
    Cantor Fitzgerald
    3/2/2022$194.00 → $102.00Outperform
    SVB Leerink
    1/21/2022$64.00Outperform
    Macquarie
    12/15/2021$189.00 → $136.00Overweight
    JP Morgan
    More analyst ratings

    $ZLAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Amado Rafael sold $188,039 worth of American Depositary Shares (10,787 units at $17.43) and converted options into 21,000 units of American Depositary Shares, increasing direct ownership by 24% to 52,391 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    1/2/26 4:15:40 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Edmondson Frazor Titus Iii sold $148,278 worth of American Depositary Shares (8,651 units at $17.14), decreasing direct ownership by 31% to 19,086 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    12/18/25 4:34:28 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairperson & CEO Du Ying gifted 303,378 units of American Depositary Shares and received a gift of 377,520 units of American Depositary Shares, increasing direct ownership by 8% to 964,161 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    12/12/25 4:42:08 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $207B Market Shift: The Race for Fast Track Approval in Oncology

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 5, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency issued over 50 oncology approvals[1], but the real story is the aggressive pivot toward targeted therapies for high-unmet-need solid tumors. That momentum has accelerated in 2026 with a sudden flurry of expedited designations[2] for RAS inhibitors and rare malignancies. This regulatory velocity creates a clear validation framework, positioning Oncolytics Biotech Inc. (NASDAQ:ONCY), Relay Therapeutics (NASDAQ:RLAY), MAIA Biotechnology (NYSE-A: MAIA), Zai Lab (NASDAQ:

    2/5/26 9:35:00 AM ET
    $AVBP
    $ONCY
    $RLAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference

    - Zocilurtatug pelitecan (Zoci) positioned to become Zai Lab's first global oncology launch, with three registration-enabling studies across 2L+ SCLC, 1L SCLC and NEC by the end of 2026 - Rapidly advancing a differentiated global pipeline, including ZL-1503 (IL-13xIL-31), ZL-6201 (LRRC15 ADC), ZL-1222 (PD-1xIL-12) and ZL-1311 (MUC17xCD3) - COBENFY approved in China, with commercial launch expected in 1H 2026 - Zai Lab to present at the J.P. Morgan Annual Healthcare Conference on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today provided an update on the Company's 2026 strategic priorities and clinical development progress. The

    1/13/26 8:00:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors

    Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that China's National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib) for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The approval is intended for patients whose disease is locally advanced or metastatic, or where surgical resection is likely to result in morbidity, and who have either progressed following prior therapies or have no satisfactory alternative treatment options. "We are pleased with the NMPA's approval of AUGTYRO for patients with NTRK-positive solid tumors. This

    1/6/26 7:30:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

    SCHEDULE 13G/A - Zai Lab Ltd (0001704292) (Subject)

    2/5/26 1:43:39 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Zai Lab Limited

    144 - Zai Lab Ltd (0001704292) (Subject)

    12/31/25 3:29:02 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Zai Lab Limited

    144 - Zai Lab Ltd (0001704292) (Subject)

    11/21/25 9:43:03 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Zai Lab with a new price target

    Jefferies resumed coverage of Zai Lab with a rating of Buy and set a new price target of $52.00

    8/25/25 8:56:24 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Zai Lab with a new price target

    Scotiabank initiated coverage of Zai Lab with a rating of Sector Outperform and set a new price target of $55.00

    3/7/25 8:00:31 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab downgraded by BofA Securities with a new price target

    BofA Securities downgraded Zai Lab from Buy to Neutral and set a new price target of $36.10 from $29.00 previously

    3/3/25 7:38:45 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Smiley Joshua L bought $289,100 worth of American Depositary Shares (10,000 units at $28.91), increasing direct ownership by 13% to 86,604 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    9/12/25 4:32:44 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    5/15/24 4:03:12 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    3/4/24 4:28:34 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Financials

    Live finance-specific insights

    View All

    Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study

    - Robust responses observed in heavily pre-treated patients with a 68% ORR for 1.6 mg/kg in second-line setting -Compelling activity in patients with baseline brain metastases (n=32), including an 80% ORR for patients without prior brain radiotherapy - Duration of response of 6.1 months across all doses and all lines of therapy; enrollment continuing for 1.2 mg/kg and 1.6 mg/kg, with nearly half of responders ongoing at data cut-off - Potential best-in-class safety profile with a low rate of Grade ≥3 TRAEs and no discontinuations in the 1.6mg/kg cohort - Global Phase 3 trial, ZL-1310-003, has initiated in second-line plus small cell lung cancer (SCLC); first-line SCLC and neuroendoc

    10/24/25 9:00:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025

    - Company to host conference call and webcast on November 6, 2025, at 8:00 a.m. ET (9:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its third quarter 2025 financial results and provide recent corporate updates on November 6, 2025, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information The live webcast can be accessed by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration link for webcast (preferred):

    10/15/25 7:30:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

    - Oral presentation to feature new data highlighting the potential of zocilurtatug pelitecan (formerly called ZL-1310) as a promising next-generation, first- and best-in-class, Delta-like ligand (DLL3)-targeted antibody-drug conjugate (ADC) for patients with extensive-stage small cell lung cancer (ES-SCLC) - Zai Lab to host investor conference call and webcast to discuss data and clinical trial plans on October 24, 2025, at 11 a.m. ET / 11 p.m. HKT Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that a late-breaking abstract (LBA) featuring new data from its global Phase 1 clinical trial (NCT06179069) evaluating zocilurtatug pelitecan (zoci), formerly known as ZL-1310, has be

    10/13/25 12:02:00 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Leadership Updates

    Live Leadership Updates

    View All

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

      Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in

    6/11/24 4:05:00 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Appoints Michel Vounatsos To Its Board of Directors

    SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023. Mr. Vounatsos brings to the Board extensive global leadership and management experience in the biopharmaceutical industry, including more than 25 years of service at leading companies. His expertise includes significant commercial experience in China and worldwide in the areas of primary care and neuroscience. "We are delighted to welcome Michel Vounatsos to the Zai Lab Board of Directors," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Michel has a wealt

    1/9/23 7:30:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZLAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zai Lab Limited

    SC 13G - Zai Lab Ltd (0001704292) (Subject)

    11/14/24 11:11:39 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zai Lab Limited

    SC 13G/A - Zai Lab Ltd (0001704292) (Subject)

    11/8/24 10:52:38 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zai Lab Limited (Amendment)

    SC 13G/A - Zai Lab Ltd (0001704292) (Subject)

    6/6/24 9:54:34 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care